Julien Valton

This inventor holds 20 USPTO granted patents and 9 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Cellectis, Pfizer Corporation, Cellectis S.a.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Julien Valton. Retrieved from https://idiyas.com/inventor/julien-valton

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 9)

% Patents Active = 85.0

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 3 (Patent Applications = 17)

Average Co-Inventor Count = 4.2

ph-index = 3

Forward Citations = 38(Granted Patents)

Location History:

Paris, FR (2016)
Charenton-le-Pont, FR (2019 - 2022)
New York, NY (US) (2019 - 2024)

Company Filing History:

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

Gene Insertion

Chimeric Antigen Receptors

Immune Cells Therapy

T Cell Engineering

Cancer Treatment

DNA Binding Domains

Tumor Microenvironment

CRS Inhibitors

NK Inhibitors

Allogeneic T Cells

Immunotherapy

Tale-Nucleases

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12774451 - METHODS FOR IMPROVING FUNCTIONALITY IN NK CELL BY GENE INACTIVATION USING SPECIFIC ENDONUCLEASE (2026-10-27),

2. 12391933 - Targeted gene insertion for improved immune cells therapy (2025-08-19),

3. 12221478 - Targeted gene integration of CRS inhibitor genes for improved immune cells therapy (2025-02-11),

4. 12209125 - Targeted gene integration of NK inhibitors genes for improved immune cells therapy (2025-01-28),

5. 11903968 - Engineered immune cells resistant to tumor microenvironment (2024-02-20),

6. 11873511 - Targeted gene insertion for improved immune cells therapy (2024-01-16),

7. 11312782 - Chimeric antigen receptors targeting B-cell maturation antigen (2022-04-26),

8. 11220683 - Method to overcome DNA chemical modifications sensitivity of engineered TALE DNA binding domains (2022-01-11),

9. 11198856 - Method for the generation of compact tale-nucleases and uses thereof (2021-12-14),

10. 11186824 - Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients (2021-11-30),

11. 11136566 - Tale-protein scaffolds and uses thereof (2021-10-05),

12. 11014989 - Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy (2021-05-25),

13. 10894093 - Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation (2021-01-19),

14. 10813951 - Method of engineering chemotherapy drug resistant T-cells for immunotherapy (2020-10-27),

15. 10526406 - Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish (2020-01-07),

Title: Julien Valton - Innovative Inventor from New York

Introduction: Julien Valton is a renowned inventor based in New York, NY, known for his groundbreaking contributions to various industries.

Latest Patents: Julien Valton holds several patents in the fields of technology, healthcare, and sustainable energy, showcasing his diverse range of expertise.

Career Highlights: With a career spanning over two decades, Julien Valton has worked with leading research institutions and companies to develop cutting-edge solutions that have revolutionized the way we live and work.

Collaborations: Throughout his career, Julien Valton has collaborated with top universities, innovative startups, and established corporations to bring his ideas to life and make a lasting impact on society.

Conclusion: Julien Valton's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.